[Pityriasis amiantacea and folliculitis decalvans : An unusual manifestation associated with antitumor necrosis factor-α therapy]. / Pityriasis amiantacea und Folliculitis decalvans : Eine ungewöhnliche Erscheinung, assoziiert mit Anti-Tumor-Nekrose-Faktor-α-Therapie.

We report on a 21-year-old woman with a 3-year history of crusts and erosions on her scalp that had appeared after starting treatment with adalimumab due to Crohn's disease. By clinicopathological correlation pityriasis amiantacea with underlying folliculitis decalvans was diagnosed. Topical and systemic antibiotic treatment showed rapid response. The occurrence of pityriasis amiantacea in folliculitis decalvans associated with tumor necrosis factor (TNF)-α inhibitor therapy is remarkable and highlights the ambivalent role of TNF-α in diseases with immunological dysfunctions in combination with infections.

Vemurafenib-induced pityriasis amiantacea: a case report.

Vemurafenib, a novel treatment for patients with BRAF-positive metastatic melanoma, is associated with a wide spectrum of cutaneous adverse events both benign and malignant. Vemurafenib-induced pityriasis amiantacea (PA), a scaling reaction of the scalp that may cause temporary or cicatricial alopecia, has not yet been reported in the literature. In the present case, PA was observed two months after the initiation of vemurafenib therapy for metastatic melanoma and managed with symptomatic treatment without the need to cease or modify the vemurafenib dosage.

Pityriasis amiantacea: a distinctive presentation of psoriasis associated with tumour necrosis factor-α inhibitor therapy.

Pityriasis amiantacea (PA; also known as tinea amiantacea) is a relatively rare but distinctive scalp condition characterized by thick scales that adhere to each other and to the hair shaft, resulting in agglomeration and matting of hair. Temporary alopecia is a common complication. Although a specific cause remains unclear, PA is associated with several inflammatory diseases such as psoriasis and seborrhoeic dermatitis. We present a case of PA as a complication of underlying psoriasis, which developed during tumour necrosis factor (TNF)-α inhibitor therapy for Crohn disease. This paradoxical cutaneous reaction to anti-TNF-α therapy has been recently described as an emerging and perplexing cause of psoriasis and psoriasiform eruptions.

[Pityriasis rosea-like eruption after anti-inflammatory and antipyretic medication].

We report 2 cases of a pityriasis rosea-like eruption after the use of the anti-inflammatory and antipyretic medications naproxen, acetaminophen, and a combination of acetylsalicylic acid and codeine phosphate. The role of these drugs in the induction of the eruption was supported by the results of macrophage migration inhibition factor and mast cell degranulation tests performed on the offending drugs.

Pityriasis rosea and discoid eczema: dose related reactions to treatment with gold.

Sixteen cases of either a pityriasiform or discoid eczematous rash occurring in patients with rheumatoid arthritis receiving treatment with gold (sodium aurothiomalate and auranofin) were studied. The results suggest that this is a dose related, not allergic, reaction to gold. The development of this rash is not an absolute indication to stop treatment with gold. Control can often be effected with potent topical steroids or a reduction in the dose or frequency of treatment with gold.

[Pityriasis rosea-like skin eruptions caused by captopril]. / Eruzione cutanea da captopril "pitiriasi rosea-like".

Captopril is an antihypertensive drug that works by inhibiting the angiotensin-converting enzyme and provokes increased levels of plasma quinine. In the case here reported a picture of pityriasis rosea-like reaction is described. The frequency of the observed and reported reactions by captopril suggests a particular caution in the use of this drug.

Pityriasis lichenoides-like eruption occurring during therapy for myelogenous leukemia.

A 61-year-old Japanese man with chronic myelogenous leukemia developed pityriasis lichenoides-like eruptions during chemotherapy. Histopathological features were also consistent with the disease. The eruption in this case may have been an allergic reaction arising in a depressed immunity induced by chemotherapy.

Pityriasis rosea and ketotifen.

A 4-year-old female patient who developed a skin eruption similar to pityriasis rosea after treatment with ketotifen (Zaditen) is presented. The relationship between ketotifen and the eruption has been based on circumstantial evidence and confirmed by the positive results of the MIF test and the rat mast cell degranulation test.

Lichenoid eruption produced by captopril.

Captopril, an oral active dipeptidylcarboxypeptidase inhibitor with antihypertensive properties, has been reported to have the following cutaneous side effects: macular and papular skin eruptions, urticaria, angioedema, mouth ulcers, pemphigus, and pityriasis rosea-like eruptions. Here, to the best of our knowledge, is the first case in which a pityriasis rosea-like eruption evolved into a lichenoid drug eruption. Also discussed is the remarkable similarity in the side effects of captopril, gold compounds, d-penicillamine, and organic mercurials.

Pityriasis rosea-like rash from captopril.

Captopril, an orally active dipeptidylcarboxypeptidase inhibitor, is a promising new antihypertensive agent. Cutaneous reactions, including (rarely) a pityriasis rosea-like eruption, are frequently associated with this therapy. Two new cases of a pityriasis rosea-like captopril-induced eruption support a pharmacologic mechanism for the eruption, since it resolved after the dosage of captopril was lowered in one patient and continued when the dosage of captopril remained unchanged in the other patient. However, the eruption later responded to therapy while use of the drug was continued. Captopril should be included among those drugs associated with a pityriasis rosea-like eruption.